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Abstract
Rationale There is now compelling evidence for a link be-
tween enteric microbiota and brain function. The ingestion of
probiotics modulates the processing of information that is
strongly linked to anxiety and depression, and influences the
neuroendocrine stress response. We have recently demonstrat-
ed that prebiotics (soluble fibres that augment the growth of
indigenous microbiota) have significant neurobiological ef-
fects in rats, but their action in humans has not been reported.
Objectives The present study explored the effects of two
prebiotics on the secretion of the stress hormone, cortisol
and emotional processing in healthy volunteers.
Methods Forty-five healthy volunteers received one of two
prebiotics (fructooligosaccharides, FOS, or Bimuno®-galacto-
oligosaccharides, B-GOS) or a placebo (maltodextrin) daily for
3 weeks. The salivary cortisol awakening response was sam-
pled before and after prebiotic/placebo administration. On the
final day of treatment, participants completed a computerised
task battery assessing the processing of emotionally salient
information.
Results The salivary cortisol awakening response was signif-
icantly lower after B-GOS intake compared with placebo.
Participants also showed decreased attentional vigilance to
negative versus positive information in a dot-probe task after
B-GOS compared to placebo intake. No effects were found
after the administration of FOS.
Conclusion The suppression of the neuroendocrine stress
response and the increase in the processing of positive
versus negative attentional vigilance in subjects supple-
mented with B-GOS are consistent with previous find-
ings of endocrine and anxiolytic effects of microbiota
proliferation. Further studies are therefore needed to test
the utility of B-GOS supplementation in the treatment
of stress-related disorders.
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Introduction
The adult human gut microbiota comprises over 1000
species and 7000 bacterial strains and is characterised
by a balanced compositional signature with moderate
inter-individual variability (Gareau et al. 2010; Cryan
and Dinan 2012). Probiotic strains, which have the
ability to confer beneficial effects upon the host, have
received renewed attention in recent years (e.g. Forsythe
and Kunze 2013). A particular focus has been put on
their ability to influence neural and endocrine systems
and behavioural phenotypes (Cryan and O’Mahony
2011; Dinan and Cryan 2012). Their potential influence
on the mechanisms underlying stress-related disorders
such as irritable bowel syndrome (IBS), anxiety and
depression is also beginning to be elucidated (Dinan
et al. 2006; Rhee et al. 2009; Mayer 2011; Bravo
et al. 2012). We have recently demonstrated in rats that
prebiotics—oligosaccharides that promote the growth of
indigenous beneficial gut bacteria such as Lactobacilli
and Bifidobacteria—also have neurotropic effects
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(Savignac et al. 2013), but the central actions of these
compounds in humans have not been reported.
Convincing evidence now exists for a role of the gut
microbiota composition in the regulation of the stress
hormone corticosterone (cortisol in humans). Raised
levels of circulating corticosterone in germ-free rodents
(Crumeyrolle-Arias et al. 2014) are reduced following
the administration of probiotics (Sudo et al. 2004), an
effect replicated in mice subjected to a stress-inducing
behavioural paradigm designed to elevate corticosterone
levels (Bravo et al. 2011). However, there is a need to
further clarify the mechanisms involved in the complex
bidirectional relationship between the stress response and
the gut microbiota (Gareau et al. 2007; Dinan and Cryan
2012).
Most indications of a ‘microbiota-gut-brain axis’ in
humans have come from patients with gastrointestinal
disorders (Brenner et al. 2009; Gareau et al. 2010; Ken-
nedy et al. 2012). Additionally, there is now preliminary
evidence for reduced subjective feelings of anxiety and
improved aspects of well-being after probiotic intake (Rao
et al. 2009; Messaoudi et al. 2011). More recently, a
functional MRI investigation found that healthy subjects
who received a fermented milk product with probiotics
showed decreased BOLD activity to an emotional atten-
tion task using facial expressions in the insula and so-
matosensory regions (Tillisch et al. 2013). These areas
play a crucial role in the integration of visceral inputs
and the processing of emotional and interoceptive infor-
mation (Craig 2009). The study demonstrates that manip-
ulations of the gut microbiota can result in measurable
changes in emotional processing in the healthy brain.
Neural and behavioural biases in the processing of emo-
tional information, in particular increased processing of threat-
related and negatively valenced stimuli, are core functional
markers of anxiety and depression (Beck 2008; Cisler and
Koster 2010). These markers are evident in symptomatic
patients (Sheline et al. 2001) as well as high-risk (Chan et al.
2007) and remitted groups (Bhagwagar and Cowen 2007),
and are essential to our understanding of disease symptom-
atology and treatment efficacy (Harmer et al. 2009; Elliott
et al. 2011). Notably, the extent to which these biases can be
modulated by pharmacological therapies in patients has been
found to be indicative of treatment response (Sheline et al.
2001; Pizzagalli 2010), and assessing novel compounds on
their ability to target emotional biases may thus provide a first
line of assessing potential clinical utility.
Our study explored the effects of two commercially
available prebiotics (fructooligosaccharides [FOS] and
Bimuno®-galactooligosaccharides [B-GOS]) on the pro-
cessing of emotional information and hypothalamic-




Forty-five volunteers (22 males, 23 females) recruited through
online and poster adverts completed the study. Inclusion
criteria were aged 18–45 years, fluent English speaker and
BMI range 18–25. Exclusion criteria were previous or current
neurological, psychiatric, gastrointestinal or endocrine disor-
ders, or other relevant medical history; current or recent
(<3 months) regular medication use; previous or current
substance/alcohol dependence or abuse within the last
3 months; regular tobacco use (>5 cigarettes/day); and partic-
ipation in research studies involving medication intake (within
3 months) or prior completion of the Emotional Test Battery
(ETB). To ensure that the enteric environment was consistent
in all volunteers, additional exclusion criteria were: no antibi-
otic use 3 months prior to the study, no regular use of pre- and
probiotics (and within 3 months prior to the study) and no
vegan diets. Finally, participants were asked to adhere to their
regular diets and avoid supplements or special diets. No
significant dietary variations were noted.
Participants were assessed with the Structured Clinical
Interview for DSM-IV (SCID; First et al. 1997) to confirm
the absence of DSM-IV axis I psychiatric conditions. The
study was approved by the Oxford Central University Re-
search Ethics Committee. All participants provided written
informed consent and were reimbursed for their time and
expenses.
Materials
Demographic and questionnaire measures
Participants completed the National Adult Reading Test
(NART; Nelson 1982) to provide an estimate of verbal IQ.
Self-report questionnaires assessing trait measures of person-
ality (Eysenck Personality Questionnaire, EPQ; Eysenck and
Eysenck 1975), stress responsivity (Perceived Stress Reactiv-
ity Scale, PSRS; Schlotz et al. 2011), subclinical symptoms of
depression (Beck Depression Inventory, BDI; Beck et al.
1961) and anxiety (State-Trait Anxiety Inventory, STAI-trait;
Spielberger et al. 1970) were also completed. Before and after
prebiotic/placebo intake (days 0 and 21, respectively), anxiety
(STAI-state) and measures of perceived stress (Perceived
Stress Scale, PSS; Cohen et al. 1983) and mood (Visual
Analogue Scales, VAS; Bond and Lader 1974; Positive and
Negative Affect Schedules, PANAS;Watson et al. 1988) were
measured using self-report questionnaires. The digit span
index of verbal working memory was used in order to monitor
group differences in executive functioning on the final day of
treatment.
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Prebiotic supplements
The study was placebo controlled, and male/female partici-
pants were randomised to receive one of two prebiotics (fruc-
tooligosaccharides [N=15; 8 males, 7 females] or Bimuno®-
galactooligosaccharides [N=15; 7 males, 8 females]) or a
placebo (maltodextrin [N=15; 7 males, 8 females]). The use
of maltodextrin as a placebo compound in prebiotic trials is
well established (Vulevic et al. 2008). Preparations were pro-
vided by Clasado Research Services Ltd., Reading, UK. Par-
ticipants took the supplements (at 5.5 g per day) in powder
form orally with breakfast for 3 weeks. The study used a
double-blind randomised design with both the participant
and the experimenter being unaware of the group they had
been allocated to.
Salivary cortisol
HPA axis activity was assessed on the day before (day 0) and
on the final day of prebiotic/placebo administration (day 21),
using the salivary cortisol awakening response (CAR;
Pruessner et al. 1997). For each CAR measurement, partici-
pants were instructed to provide five saliva samples (using
Salivettes, Sarstedt Ltd., Nümbrecht, Germany) taken in their
own home immediately upon waking and subsequently every
15 min until 1 h post-waking. Saliva samples were stored at
4 °C prior to analysis. Cortisol was measured using a com-
mercial ELISA (Salimetrics Europe Ltd., Newmarket, UK),
within 7 days of sample collection.
Emotional processing tasks
On the final day of prebiotic/placebo intake (day 21), partic-
ipants completed a validated computerised test battery
assessing the processing of emotional stimuli (the ETB;
Harmer et al. 2004).
Attentional dot-probe task
Sixty negative and 60 positive words were paired with
neutral words matched for length. On each trial, a fixation
cross was presented for 500 ms in the centre of the screen,
followed by two words presented at the top and bottom of
the screen. In the unmasked condition, the words were
presented for 500 ms. In the masked condition, word pairs
were presented for 17 ms after which a mask was
displayed for 483 ms. Masks were constructed from
digits, letters and non-letter symbols and were matched
for word position and length. Words or masks were re-
placed by a probe of either one or two stars in the location
of one of the preceding stimuli (probes were presented at
the top or bottom of the screen with equal frequency).
Participants were instructed to indicate the number of
stars as quickly and accurately as possible using two
labelled keys. A key press terminated the probe presenta-
tion and trial. There were 180 trials in total (30 positive-
neutral, 30 negative-neutral, 30 neutral-neutral word pairs
each for masked and unmasked conditions), and emotion-
al words were presented at the top and the bottom location
with equal frequency. Masked and unmasked trials were
presented in random order. Reaction time and accuracy
scores were recorded, and attentional vigilance scores
were calculated for each participant by subtracting the
reaction time from trials when probes appeared in the
same position as the emotional word (congruent trials)
from those trials when probes appeared in the opposite
position to the emotional word (incongruent trials).
Facial expression recognition task
In the facial expression recognition task (FERT), the percep-
tion of six basic emotions (happiness, surprise, sadness, fear,
anger, disgust) or a neutral expression (taken from the Pictures
of Affect Series; Ekman and Friesen 1976) was assessed. Each
emotion was shown at 10 morphed intensity levels from
neutral to maximum emotional expression (Young et al.
1997) leading to a total of 250 randomly presented stimuli.
Each stimulus was presented for 500 ms and replaced by a
grey screen until the participant responded (as quickly and as
accurately as possible) by selecting a key corresponding to
one of the basic emotions. The outcome measures were clas-
sification accuracy, number of misclassifications and reaction
times.
Emotional categorisation and memory
Sixty words representing either disagreeable (N=30) or
agreeable (N=30) personality characteristics (from
Anderson 1968) and matched for meaningfulness, word
frequency and word length were presented on a computer
screen for 500 ms each. Participants were asked to cate-
gorise each word as quickly and accurately as possible
according to whether they would like or dislike to be
described by it. After completion, participants were
instructed to recall and write down as many words as they
could within a 2-min time limit. Subsequently, partici-
pants were instructed to categorise words presented on
the screen into those which were previously presented
(60 target words) or those which were novel words (60
matched distracter words). Outcome measures for the
emotional categorisation were classifications and reaction
times. For the memory recall, the number of correct
responses and false positives was recorded, and partici-
pants’ memory recognition was assessed using correct
responses, false positives and reaction times.
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Statistical analysis
Demographic and questionnaire values were analysed using
one-way ANOVA with group as factor. Salivary cortisol
values (in nmol/l) were square root transformed and analysed
in a mixed design ANOVAwith time point of sampling (0, 15,
30, 45 and 60 min after waking) and day of sampling (pre- vs.
post-treatment) as repeated-measures variables and prebiotic
treatment group (placebo, FOS or B-GOS) as a between-
subjects variable. Raw cortisol values are presented for clarity.
The behavioural outcome variables of the ETB were also
analysed with mixed design ANOVAs, with prebiotic treat-
ment group as between-subjects factor and emotion and task
condition as within-subjects factors. Significant interactions
were followed up using main effects analyses. Greenhouse-
Geisser corrections were used where assumptions of spheric-
ity were not met.
Results
Baseline measures and compliance
There were no significant differences between groups for age,
trait measures of anxiety, stress reactivity, neuroticism or
cognitive status as assessed by digit span (see Table 1). This
suggests that groups were well matched between the two
prebiotic and placebo conditions.
Out of 48 participants, three participants did not complete
the full course of prebiotic/placebo intake and were excluded
from all analyses, leading to the final sample of 45 partici-
pants. Participants completed a checklist each day to monitor
prebiotic/placebo intake, and none reportedmissing more than
two intakes (0 missed=41, 1 missed=3, 2 missed=1).
Hormonal contraceptive use and menstrual cycle
Of the 23 female participants, 13 used hormonal methods of
contraception. Menstrual cycle phase was reported by 16
females, and an additional two female participants reported
no or very infrequent menses due to hormonal contraceptive
use—these were coded as a separate group. Cycle phase was
analysed according to the following phases (based on aver-
ages from Wolfram et al. 2011; Fehring et al. 2006): menses
(days 1–6), follicular phase (days 7–12), ovulation phase
(days 13–19), luteal phase (day 20–end of cycle). In order to
test the between-subjects effects of contraceptive use on the
waking cortisol response, repeated-measures ANOVAs were
performed on the cortisol level uponwaking (first sample) and
the cortisol area under the curve with respect to ground (AUC-
g) including the factor supplement group to test for potential
interactions.
There was no significant difference in the number of
females who took hormonal contraceptives between the
groups (χ2=3.45, p>0.1). The effect of hormonal con-
traceptive on the first sample of salivary cortisol after
waking showed a trend for lower levels in females
taking contraceptives compared to those who were not
(mean (SD)=8.20 (3.42) vs. mean (SD)=10.65 (4.37),
F(1,17)=3.74, p=0.07); however, this difference was
stable across days of testing and treatment groups (all
interactions’ p values >0.7). The effect of hormonal
contraceptives on cortisol AUC-g was not significant
(F(1,17)=3.01, p>0.1), and there were no significant
interactions with testing day or treatment group
(all p>0.1).
The number of participants who were in a particular cycle
phase at the time of testing did not differ between the groups
(χ2=8.75, p>0.1). Due to insufficient power, the effects of
menstrual phase on cortisol or attention were not tested with
ANOVAs.
Table 1 Baseline characteristics
of participants by treatment group Measure Mean (SD) p
Placebo FOS B-GOS
Age, in years 23.27 (3.86) 24.53 (3.87) 23.27 (3.95) 0.31
NART score 116.50 (5.11) 115.71 (5.24) 112.62 (5.99) 0.18
EPQ, neuroticism 5.17 (4.61) 5.64 (4.22) 4.38 (3.36) 0.73
Perceived Stress Reactivity Scale 16.92 (10.06) 16.86 (6.95) 14.38 (5.66) 0.64
Beck Depression Inventory 2.58 (4.21) 2.14 (3.04) 2.54 (2.76) 0.93
Spielberger Anxiety Inventory, trait 32.00 (10.33) 32.86 (5.41) 31.69 (4.80) 0.91
Digit span, forward 10.08 (1.38) 8.43 (2.31) 8.54 (2.60) 0.12
Digit span, backward 8.50 (1.98) 6.79 (2.52) 7.69 (2.29) 0.18
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Cortisol
Salivary cortisol did not differ significantly between groups at
baseline but was significantly lower following B-GOS com-
pared with placebo (Fig. 1). This was shown by an ANOVA
interaction effect of pre- versus post-treatment, group
(placebo, FOS or B-GOS) and sampling time point (in
minutes post-waking) on salivary cortisol levels, followed
up with separate group×time point ANOVAs for each day
of sampling (day 0: main effect of group F(2,41)=1.08, n.s.;
day 21: main effect of group F(2,41)=4.20, p<0.05, followed
up with Sidak-corrected contrasts: placebo vs. GOS, p=0.02,
all others p>0.1). Main effects analyses of the day×group×
time ANOVA confirmed that cortisol levels were increased
post-waking 15, 30, 45 and 60 min after waking (significant
main effect of time F(2.41,98.63)=58.61, p<0.001, planned
follow-up contrasts all significant at p<0.001). The main
effects of day of sampling and treatment group were not
significant (p>0.1). Gender was not entered as a factor of
interest due to insufficient power.
The lowered CAR in the B-GOS compared to the placebo
group on day 21 of supplement administration was also con-
firmed when analysing area under the curve with respect to
ground (Fig. 2; day×group ANOVA on square-root-
transformed salivary cortisol values: day×group interaction
[F(2,41)=3.52, p=0.039], followed up with separate group
ANOVAs for pre/day 0 [F(2,41)=1.24, n.s.] and post/day 21
[F(2,41)=4.12, p=0.023, follow-up contrasts: placebo vs. B-




There was a significant group×emotion×masking condition
interaction in the visual dot-probe task (group×emotion×
masking condition [F(2,41)=3.14, p=0.05]). As can be seen
in Fig. 3, this effect was driven by decreased attentional
vigilance to negative versus positive information in the
unmasked condition (Fig. 3b), with no significant main effects
or interactions in the masked condition (Fig. 3a; valence×
group interaction in unmasked: F(2,41)=4.29, p=0.02;
masked: F(2,41)=0.85, p>0.1). Follow-up analyses with sep-
arate ANOVAs for prebiotic group compared with placebo in
the unmasked condition confirmed this effect as driven by
increased positive versus negative vigilance after B-GOS
compared to placebo, while the FOS group did not perform
differently to placebo (B-GOS vs. placebo: valence×group
F(1,27)=6.94, p=0.014, FOS vs. placebo: valence×group
F(1,27)=3.20, n.s.).
FERT
There were no significant effects of prebiotic treatment on
measures of accuracy (main effect of group: F(2,42)=1.71,
n.s., emotion×group interaction F(7.83,164.52)=0.67, n.s.).
Analysis of reaction time data revealed no significant interac-
tion between group and emotion (main effect of group:
F (2 ,42) = 0.53, n .s . ; emot ion × group interac t ion
F(8.16,773.38)=1.10, n.s.).
Emotional categorisation, recall and recognition
Participants responded faster to positive (mean reaction
time=1031 ms, SD=228 ms) compared to negative
(mean reaction time=1083 ms, SD=200 ms) self-
referential personali ty words in the emotional
categorisation task (valence×group ANOVA, main effect
of valence: F(1,42)=12.82, p<0.01) and in the emotion-
al word recognition task (mean reaction time to positive
words=1220.92, SD=263.03; mean reaction time to
negative words=1381.07, SD=348.13; main effect of
valence: F(1,41)=23.34, p<0.001); however, there was
no significant main effect of prebiotic treatment group
(F(2,42)=0.80, p>0.1) and the relative speeding for
positive words did not differ between groups (emo-
tion×group F(2,42)=0.35, p>0.1). Positive words were
also remembered more often than negative words in
both the surprise recall task (mean accuracy, positive
words = 7.41 (SD = 2.45) , negat ive = 5.70 (2.29);
F(1,41)=16.16, p<0.001) and in the recognition task
Fig. 1 Cortisol awakening response before and after administration of placebo, B-GOS or FOS. There were no differences in the salivary CAR pre-
administration. Salivary cortisol awakening response was significantly lower after 3 weeks of B-GOS intake, but not FOS intake, compared with placebo
Psychopharmacology (2015) 232:1793–1801 1797
(mean correct recognition, positive words=25.67 (SD=
3.41), negative words=22.36 (SD=3.88); F(1,41)=
53.54, p<0.001), but these effect did not differ between
groups (p>0.1).
Self-report questionnaires
There were no significant effects of group on self-report
measures of state anxiety or perceived stress before or after
prebiotic/placebo administration (see Table 2). Furthermore,
there were no group differences in the overall cognitive status
as assessed by digit span on the day of psychological testing.
Correlational analyses
To test the hypothesis that cortisol levels were associated with
changes in attentional dot-probe performance in the B-GOS
group, we correlated difference scores of positive versus neg-
ative reaction times in the unmasked condition with absolute
cortisol levels upon waking on the day of testing and with the
difference in pre- versus post-prebiotics cortisol values (day
0–day 21). There were no associations of cortisol with atten-
tional performance (all p>0.1).
Discussion
The current study explored the neuroendocrine and affective
effects of two types of prebiotic supplements in healthy hu-
man volunteers, using salivary CAR and a validated test
battery of emotional processing. Results revealed that B-
GOS prebiotic intake was associated with decreased waking
salivary cortisol reactivity and altered attentional bias com-
pared to placebo. These results are consistent with previously
found anxiolytic-like effects of probiotics and reveal key
differences between two different prebiotic supplements.
Our findings of lowered cortisol awakening reactivity in
the group receiving B-GOS prebiotics compared to the place-
bo group indicate that prebiotic administration may modulate
HPA activity in a similar fashion as the administration of
probiotic strains directly seen in rodents (Sudo et al. 2004;
Gareau et al. 2007) and humans (Messaoudi et al. 2011). The
cortisol awakening response is a reliable marker of HPA axis
activity which has been found to be increased by work
stressors (Pruessner et al. 1997; Kunz-Ebrecht et al. 2004)
and in individuals at high risk of depression (Mannie et al.
2007). Insufficient or excessive cortisol reactivity may indi-
cate dysfunctional HPA axis feedback mechanisms, which
may provide useful targets for modulation by treatments in
certain vulnerability or disease states (Pariante and Lightman
2008; Dinan and Cryan 2012).
Participants receiving B-GOS supplements showed in-
creased attentional vigilance to positive versus negative stim-
uli on the dot-probe task. Our effects are similar to those seen
following administration of pharmacological agents such as
the selective serotonin reuptake inhibitor citalopram or the
benzodiazepine diazepam in healthy individuals (Browning
et al. 2006; Murphy et al. 2009a, b). These effects have been
interpreted as showing an early anxiolytic-like profile, where
threatening stimuli are less likely to be attended to (Harmer
2010). Interestingly, we found effects of the B-GOS prebiotic
administration on altered attentional processing only in the
unmasked condition (500 ms presentation) of the dot-probe
task. Attentional vigilance to brief, masked presentations of
threatening cues has primarily been interpreted as an
Fig. 2 Area under the curve (with respect to ground) of salivary cortisol
awakening response pre- and post-prebiotic supplement/placebo intake.
*p<0.05
Fig. 3 Vigilance reaction times in the attentional dot-probe task. a
Attentional vigilance did not differ between groups during masked trials
of the attentional dot-probe task. b Participants showed decreased
attentional vigilance to negative versus positive words in the unmasked
condition of the dot-probe task after B-GOS but not FOS intake compared
to placebo
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involuntary deployment of attention (Browning et al. 2010),
whereas at longer stimulus durations, it may further involve a
difficulty to disengage from salient emotional stimuli (Koster
et al. 2004; Cisler and Koster 2010). Research suggests that
while responses to masked stimuli may be particularly prev-
alent in anxiety disorders rather than depression, attentional
bias seen at longer exposure durations may also be of rele-
vance to depression. The increase of positive compared to
negative emotional information processing in the B-GOS
group provides initial evidence that behavioural effects of
probiotics in rodent models (Bravo et al. 2011) can be extend-
ed to affective processing in humans using prebiotics. These
results are also consistent with a recent fMRI study which
reported that a 3-week probiotic administration reduced neural
response in a network of areas (including the somatosensory
cortex, insula and parahippocampal gyrus) to angry and fear-
ful facial expressions (Tillisch et al. 2013).
Differences in attentional resource allocation to negative or
positive stimuli are associated with individual variability in
trait and state measures. Specifically, vigilance to cues of
threat or danger is greater in highly anxious individuals com-
pared with low-anxious individuals and healthy controls
(Mogg et al. 1994; Bradley et al. 1998; Koster et al. 2005),
and threat-related processing is believed to play a key role in
the symptomatology of anxiety and its modulation by anxio-
lytics (Beck and Clark 1997; Mogg and Bradley 1998). Phar-
macological anxiolytics and antidepressants that are clinically
effective in reducing symptoms have been found to affect
reductions in specific negative biases in neural correlates of
emotional information processing (Sheline et al. 2001; Fu
et al. 2004; Godlewska et al. 2012), and also modulate biases
when administered in healthy control and at-risk groups
(Harmer et al. 2003; Browning et al. 2006; Murphy et al.
2009b). Based on the initial results of gut microbiota inter-
ventions, it is now crucial to investigate the extent and spec-
ificity of information processing biases that may be targeted
by different gut microbiota manipulations and whether they
prove clinically beneficial.
Although we were unable to test the mechanisms of action
directly through characterisation of gut microbiota, a previous
characterisation of B-GOS and FOS prebiotics showed
pronounced increases in bifidobacteria in faecal pellets of rats
treated with B-GOS administration compared to placebo, with
more moderate effects following the FOS intervention
(Savignac et al. 2013). The specificity of galacto-
oligosaccharides affecting behavioural and endocrine changes
is thus in line with previous findings of galacto-
oligosaccharides as particularly effective in stimulating enteric
microbial growth (Abou Hachem et al. 2013). Of course, the
possibility of an additional, direct effect of B-GOS on the gut
mucosa [10] cannot be ruled out.
Given the lack of association between altered attentional
processes and a reduction in the salivary cortisol awakening
response (CAR), we were unable to confirm a moderating
effect of cortisol reactivity on behaviour. Although there is
strong evidence for a role of the gut microbiota in the regula-
tion of the HPA axis (see Dinan and Cryan 2012 for a review),
the exact mechanisms by which they interact with central
effects remain to be investigated. One potential mechanism
of action underlying these effects is via anti-inflammatory and
immune responses following probiotic proliferation (Lyte
2011; Ait-Belgnaoui et al. 2012), and central effects of
probiotics have been found to be vagus nerve dependent
(Bravo et al. 2011).
While initial results of the B-GOS prebiotic on the cortisol
awakening response are promising, we had insufficient power
to investigate gender effects, which have previously been
reported (Pruessner et al. 1997). Further, there were no effects
of either prebiotic on the remaining tasks of the ETB which
examine aspects of facial expression recognition, self-
referential processing and emotional memory. The current
results also differ from previous findings that indicate subjec-
tive anxiolytic effects of probiotics (Rao et al. 2009;
Messaoudi et al. 2011) as we found no effects of prebiotics
on subjective measures of subclinical anxiety or perceived
stress. One improvement may be to extend the administration
period of prebiotics as probiotics take several weeks to prolif-
erate. It is also possible that these results are in part due to our
study population of young healthy volunteers with low sub-
clinical scores and presumably healthy gut microbiota com-
positions even before treatment. Studying a population with a
potential deficiency in their gut microbiota compositions, for
Table 2 State measures of
anxiety and perceived stress
(mean, SD) before and after
prebiotic/placebo administration
and cognitive status on day of
assessment (day 21)
Measure Mean (SD) p
FOS Placebo B-GOS
Spielberger Anxiety Inventory, state Pre (day 0) 32.00 (7.13) 32.92 (10.03) 32.15 (9.11) 0.96
Post (day 21) 30.00 (5.53) 30.17 (7.55) 31.31 (5.23) 0.84
Perceived Stress Scale Pre (day 0) 9.86 (4.64) 9.92 (6.05) 10.77 (3.77) 0.87
Post (day 21) 9.57 (5.20) 8.92 (5.40) 10.46 (4.86) 0.75
Digit span (post, day 21) Forward 9.71 (2.40) 10.25 (1.96) 9.54 (2.44) 0.72
Digit span (post, day 21) Backward 7.50 (2.82) 8.25 (2.73) 8.62 (2.66) 0.56
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example elderly individuals or IBS patients with comorbid
psychiatric symptoms, may improve power. The applicability
of our results to other populations—such as those with dete-
rioration in the health of their intestinal gut flora or HPA axis
abnormalities—is a valid next step for future study.
We found a selective modulation of attention to emotional
stimuli and HPA axis reactivity following B-GOS prebiotic
supplement in healthy participants, supporting a key role for
gut microbiota in the regulation of affective function. This, to
our knowledge, is the first study extending findings of the
central effects of probiotics to behavioural effects of prebiotics
in humans.
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